Eli Lilly and (LLY) & SCYNEXIS (SCYX) Critical Analysis
Eli Lilly and (NYSE: LLY) and SCYNEXIS (NASDAQ:SCYX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitabiliy, analyst recommendations, earnings, valuation, institutional ownership, risk and dividends.
Insider & Institutional Ownership
75.6% of Eli Lilly and shares are held by institutional investors. Comparatively, 46.3% of SCYNEXIS shares are held by institutional investors. 0.2% of Eli Lilly and shares are held by insiders. Comparatively, 3.9% of SCYNEXIS shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Valuation & Earnings
This table compares Eli Lilly and and SCYNEXIS’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Eli Lilly and||$22.00 billion||3.94||$5.99 billion||$2.31||35.53|
Eli Lilly and has higher revenue and earnings than SCYNEXIS.
This is a summary of current recommendations and price targets for Eli Lilly and and SCYNEXIS, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Eli Lilly and||1||6||11||0||2.56|
Eli Lilly and presently has a consensus target price of $89.18, suggesting a potential upside of 8.66%. SCYNEXIS has a consensus target price of $11.25, suggesting a potential upside of 603.13%. Given SCYNEXIS’s stronger consensus rating and higher probable upside, analysts clearly believe SCYNEXIS is more favorable than Eli Lilly and.
This table compares Eli Lilly and and SCYNEXIS’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Eli Lilly and||11.12%||28.71%||10.74%|
Volatility and Risk
Eli Lilly and has a beta of 0.34, suggesting that its share price is 66% less volatile than the S&P 500. Comparatively, SCYNEXIS has a beta of 0.34, suggesting that its share price is 66% less volatile than the S&P 500.
Eli Lilly and pays an annual dividend of $2.08 per share and has a dividend yield of 2.5%. SCYNEXIS does not pay a dividend. Eli Lilly and pays out 90.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Eli Lilly and has increased its dividend for 2 consecutive years.
Eli Lilly and beats SCYNEXIS on 9 of the 15 factors compared between the two stocks.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company’s human pharmaceutical products include endocrinology products, neuroscience products, oncology products, immunology products and cardiovascular products. The Company’s animal health products segment includes products for food animals and products for companion animals. As of December 31, 2016, the Company manufactured and distributed its products through facilities in the United States, Puerto Rico and 14 other countries.
SCYNEXIS Company Profile
SCYNEXIS, Inc. is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains. The Company also conducts additional in vitro and in vivo studies to further characterize the spectrum of activity of SCY-078. The Company has completed multiple Phase I studies with the oral formulation of SCY-078 and is conducting its first Phase I study with the IV formulation of SCY-078. The Company has also developed a platform for cyclophilin inhibitors, which has two clinical stage compounds, such as SCY-635 and SCY-641.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.